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Many recent studies have reported that patients infected with novel coronavirus 2019 or SARS-CoV-2 (Severe Acute 
Respiratory Syndrome Coronavirus 2) might have a liver injury. However, few studies have focussed on the levels of 
Gamma glutamyl-transferase (GGT) alone and the variations associated with it. We retrospectively analysed the GGT levels 
of 476 admitted patients with confirmed COVID-19 in a tertiary care centre, PGIMER (Post Graduate Institute of Medical 
Education and Research), Chandigarh. Out of the total 476 COVID-19 patients studied, 35% had elevated GGT levels. ICU 
care was required for 51.19% (P <0.0001) of these patients and their hospital stay was of longer duration as compared to the 
patients with normal GGT levels. The incidence of GGT elevation was found to be more pronounced in males and elderly 
patients. The male population displayed higher GGT levels with 52% having raised levels compared to females where only 
21.6% had elevated GGT levels. Although the number of COVID-19 cases was majorly from young age groups, the 
elevation in GGT levels has been reported more in elderly patients. GGT levels can therefore serve as a predictor for the 
extent of liver injury and severity in COVID-19 patients. 
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The current Coronavirus disease 2019 (COVID-19) 
pandemic, triggered by SARS-CoV-2 virus has spread 
rapidly throughout the world with high rates of 
transmission and substantial mortality and has severely 
impacted the living and working conditions of billions of 
people. As of 9 October 2020, there have been 36, 361, 
054 confirmed cases of COVID-19, including 1, 056, 
186 deaths, reported to WHO
1
. This emerging severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causal agent of COVID-19, although primarily 
targets the upper respiratory tract, many studies have 
indicated that the liver, among other organs, may also be 
affected by the virus
2,3
. Similarly, liver damage was 
reported to occur during the infection of another 
pathogenic coronavirus; the severe acute respiratory 
syndrome coronavirus (SARS-CoV), and the Middle 
East respiratory syndrome coronavirus (MERS-CoV)
4,5
. 
As with SARS-CoV, angiotensin-converting 
enzyme 2 (ACE2) appears to be the susceptible 
receptor for SARS-CoV-2 and is expressed in more 
than 80% of alveolar cells in the lungs
6
. ACE2 
receptors expression is also observed in smooth 
muscles of the gastrointestinal tract
7
 and squamous 
epithelium of the nasal, oral and nasopharyngeal 
mucosa
8
. Hepatic distribution of the ACE2 receptor is 
unique as it is mostly expressed in cholangiocytes 
(59.7%) than hepatocytes (2.6%)
9
. Markers for 
hepatic cholangiocytic activity which are primarily 
assessed by measurements of serum alkaline 
phosphatase (ALP) and Gamma glutamyl-transferase 
(GGT) are hence important. 
Infection with SARS-CoV-2 and its association 
with an increased risk for an abnormal liver function 
could either be a transient biochemical abnormality or 
a significant indicator of liver injury observed during 
the course of infection. Few authors consider this 
feature not to be clinically significant
10-14
, while others 
have highlighted this association with adverse 
outcomes
15-17
 or reduced survival
15-20
. This controversy 
can be explained in part due to the lack of a consensus 
on the definition of COVID-19 associated liver injury
21
. 
Therefore, generating valid evidence for potential 
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variability in COVID-19 related liver injury 
particularly about the hepatic cholangiocytic activity as 
measured by GGT levels is relevant and paramount. 
 
Methods 
Study Design and participants 
We retrospectively evaluated and analysed the 
GGT levels of 494 patients of both genders with 
confirmed COVID-19 from March 15, 2020, up to 
August 15, 2020, admitted in Nehru Hospital 
Extension (NHE), designated COVID Care Centre at 
Post Graduate Institute of Medical Education and 
Research (PGIMER), Chandigarh, India. Out of these 
494 patients, 18 patients suffering either from chronic 
liver diseases, alcoholic patients or hepatitis positive 
patients were excluded from the study, hence, 476 
patients were included in the study. The study was 




The diagnosis for COVID-19 was confirmed by  
RT-PCR analysis of nasopharyngeal and 
oropharyngeal swab samples in the Department of 
Virology, PGIMER, Chandigarh, India as per 
guidelines of Indian Council of Medical Research 
(ICMR), New Delhi, India.   
Following standard operating procedures, the blood 
samples were handled by a designated technician with 
proper safety gear. The sample tubes were 
decontaminated by wiping and spraying with 0.1% 
hypochlorite solution, which was followed by placing 
the vacutainers under UV-C Biosafety Cabinet for 15 
min. The samples were then centrifuged for 10 min at 
3500 RPM; the lid of the centrifuge was kept closed 
for the next 15 min for the aerosols to settle down. 
The serum samples for GGT tests were analysed after 
maintaining a proper quality control check in Roche 
Cobas 8000 Autoanalyzer. All tests were performed 
according to standard protocols and procedures. 
Abnormality in GGT levels was defined as  
levels >61 U/L on the day of admission
22
.We have 
taken the requirement of the Intensive Care Unit as a 
primary outcome and median hospital stay as a 




GraphPad Prism 8.0 software was used for 
statistical analysis. Descriptive analysis and Fischer 
exact test were performed. 
Results 
Recruited patients for the study were 476. Out of 
these, raised levels of GGT were found in 168 (35%, 
Fig. 1) with a median GGT value of 106 and a 
maximum GGT value of 682 (11× upper limit of 
normal, Table 1). 
Out of these 168 patients with raised GGT levels, 
ICU care was required for 51.19% of the patients, 
while only 22.07% of patients with normal GGT 
levels required ICU care. This finding was found to 
be statistically significant with a P value <0.0001 
(Fig. 2A). Also, median days of hospital stay in 
patients with elevated GGT levels were 6 days as 
compared to 4 days in patients with normal GGT 
levels (Fig. 2B). 
This increase was more prevalent in males with 
127 out of 287 (44%) as compared to females, where 
elevated GGT levels were found only in 41 out of 189 
(21.6%) (Fig. 3A). Although no significant difference 
was found in the median values of GGT between 
these groups, i.e. 107 and 102 in males and females 
with increased enzyme levels, respectively, (Fig. 3B 
and Table 2). 
 
 
Fig. 1 — Pie chart showing the percentage of patients with normal 
and increased GGT levels 
 
Table 1 — Table showing the GGT values in the different  
groups of total subjects 






Number of values 476 308 168 
Minimum GGT 
value (U/L) 
4.420 4.420 62.00 
25% Percentile 
(U/L) 
20.00 15.00 81.25 
Median GGT value 
(U/L) 
37.00 23.00 106.0 
75% Percentile 
(U/L) 
84.00 35.50 188.0 
Maximum GGT 
value (U/L) 
682.0 61.00 682.0 




Also, the incidence of GGT surge is reported to be 
age-dependent as we found a concomitant increase in the 
percentage of patients with abnormally high GGT levels 
with increasing age. Out of the total patients falling under 
age groups, 13-39 years, 40-59 years and >60 years, the 
percentage of patients with elevated GGT levels was 
found to be 24.51%, 42.59%, and 49.45%, respectively, 
(Fig. 4A). The median GGT values were found to be 
 
 
Fig. 3 — (A) The gender-wise distribution of the total number of patients, patients with normal GGT levels, and patients with increased 
GGT levels; and (B) The levels of GGT in females and males with increased enzyme levels with median values 
 
 
Fig. 2 — (A) The comparison of the number of patients admitted 
in ICU in normal, and elevated GGT groups (P <0.0001); and  
(B) Median days of hospital stay in normal and elevated GGT 
groups (P = ns) 
Table 2 — Table showing the GGT values in female and male 
populations with raised levels of enzymes 
 Female Male 
Number of values 41 127 
Minimum GGT value (U/L) 62.00 62.00 
25% Percentile (U/L) 81.00 81.00 
Median GGT value (U/L) 102.0 107.0 
75% Percentile (U/L) 228.0 180.0 




Fig. 4 — (A) The percentage of patients with increased GGT values 
under different age groups; and (B) The levels of GGT in patients 
with increased enzyme levels falling under different age groups 
 




155.5, 99.5, 109 and 105 in age groups, <13 years, 13-39 
years, 40-59 years and >60 years, respectively, (Fig. 4B, 
& Table 3). The median age with maximum GGT levels 
was found to be 48 years (Table 4). 
Although the number of patients admitted in the 
hospital was more from the young age group i.e. 204 
belonging to age group 13-39 years, followed by  
162 and 91 from age groups 40-59 years and  
>60 years, respectively, the incidence of GGT 
increase was found to be more in later groups. As 
patients with age <13 years were less than 20 in 




The study was retrospectively carried out in 476 
COVID-19 positive patients. Out of the total admitted 
patients, 168 (35%) had elevated GGT levels. The 
increase in GGT was more prevalent in males with 
127 out of 287 (44%) as compared to females with 41 
out of 189 (21.6%). Elevated GGT levels were 
observed more in the elderly age group as compared 
to the younger patients with COVID-19 which is 
consistent with the previous reports, that patients of 
older age had more severe illness and the incidence 
rate was higher in men
23
. 
The median GGT value in patients with increased 
GGT was 106 and the maximum GGT value observed 
was of 682 U/L (11× upper limit of normal). The  
median age of patients with elevated GGT levels was  
48 years.  
Another vital observation in our study was that the 
majority of the COVID-19 positive patients with raised 
GGT levels required admission in the intensive care 
units (ICU). It was observed that only 22.07% of 
patients with normal GGT levels required ICU  
care whereas 51.19% of patients with raised GGT  
levels required ICU admission. This finding was  
found to be statistically significant with P <0.0001.  
The average hospital stay duration in patients  
with elevated GGT levels was 6 days whereas in patients 
with normal GGT levels were 4 days after admission. 
These observations clearly indicate that elevated GGT 
was more marked in patients with severe manifestations 
of SARS-CoV-2 infection, thereby requiring ICU 
admission. 
There are studies reporting similar findings that 
patients in intensive care units and critical states are 
more likely to have their liver biochemical markers 
deranged denoting the severity of infection
24
. 
Elevated levels of GGT reported to be highest at the 
time of admission corresponding with the outcomes 
that have been presented in a number of studies
25-26
. In 
a recently conducted study, it was found that at 
intervals of admission into isolation wards, the 
elevation of GGT was highest. Our study showed the 
association of elevated GGT levels with an increased 
number of ICU admissions. 
We also observed in our study that the maximum 
patients with COVID-19, 204 out of 476 were in the 
age group of 13-39 years as compared to the other age 
groups. This age group reflects the mobile and active 
group in a population. In a study that examined the 
relationship between COVID-19 transmissions with 
mobility, a statistically significant correlation was 
seen between social distancing, measured by mobility 
patterns and subsequent reduction in COVID-19 
cases. This could explain the increased incidence of 
COVID-19 infection in the particular age group.  
Our study also has its limitations. It is a retrospective 
study carried out using the data collected from a single 
Table 3 — Table showing the GGT values in different age groups 
with increased levels of enzymes 








Number of values 6 50 69 43 
Minimum GGT value 
(U/L) 
78.00 63.00 62.00 62.00 
25% Percentile (U/L) 97.75 78.75 82.00 82.50 
Median GGT value (U/L) 155.5 99.50 109.0 105.0 
75% Percentile (U/L) 232.0 174.5 184.0 218.5 
Maximum GGT value 
(U/L) 
317.0 682.0 519.0 494.0 
 
Table 4 — Table showing the age-related distribution in  









Number of values 476 308 168 
Minimum Age 
(years) 
<1 <1 <1 
25% Percentile 
(years) 
29 30 35 
Median Age (years) 40 42 48 
75% Percentile 
(years) 
55 56 60 
Maximum Age 
(years) 
94 87 94 




centre. Medication and clinical history of the patients 
were not included. We examined exclusively the role of 
GGT in COVID-19 and have not considered the role of 
other liver enzymes and inflammatory markers. 
Therefore, more studies documenting the derangements 
of liver enzymes during hospitalization and their relation 
to clinical outcomes of the patients are required. Liver 
injury COVID-19, as a result of ACE2 receptor-
associated bile duct endothelial disruption and 
derangements of cholestatic liver enzymes needs more 




COVID-19 can cause derangements in liver profile. 
The abnormal liver function could be associated  
with raised GGT levels. Abnormal liver profile is 
found to be more pronounced in males and elderly 
patients, thereby requiring extensive treatment. 
Markers of liver function could therefore serve as an 
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